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Abstract
Background: The polyamines putrescine, spermidine, and spermine are organic cations that are required for cell growth
and differentiation. Ornithine decarboxylase (ODC), the first and rate-limiting enzyme in the polyamine biosynthetic
pathway, is a highly regulated enzyme.
Methodology and Results: To use this enzyme as a potential drug target, the gene encoding putative ornithine
decarboxylase (ODC)-like sequence was cloned from Entamoeba histolytica, a protozoan parasite causing amoebiasis. DNA
sequence analysis revealed an open reading frame (ORF) of ,1,242 bp encoding a putative protein of 413 amino acids with
a calculated molecular mass of 46 kDa and a predicted isoelectric point of 5.61. The E. histolytica putative ODC-like
sequence has 33% sequence identity with human ODC and 36% identity with the Datura stramonium ODC. The ORF is a
single-copy gene located on a 1.9-Mb chromosome. The recombinant putative ODC protein (48 kDa) from E. histolytica was
heterologously expressed in Escherichia coli. Antiserum against recombinant putative ODC protein detected a band of
anticipated size ,46 kDa in E. histolytica whole-cell lysate. Difluoromethylornithine (DFMO), an enzyme-activated
irreversible inhibitor of ODC, had no effect on the recombinant putative ODC from E. histolytica. Comparative modeling of
the three-dimensional structure of E. histolytica putative ODC shows that the putative binding site for DFMO is disrupted by
the substitution of three amino acids—aspartate-332, aspartate-361, and tyrosine-323—by histidine-296, phenylalanine-305,
and asparagine-334, through which this inhibitor interacts with the protein. Amino acid changes in the pocket of the E.
histolytica enzyme resulted in low substrate specificity for ornithine. It is possible that the enzyme has evolved a novel
substrate specificity.
Conclusion: To our knowledge this is the first report on the molecular characterization of putative ODC-like sequence from
E. histolytica. Computer modeling revealed that three of the critical residues required for binding of DFMO to the ODC
enzyme are substituted in E. histolytica, resulting in the likely loss of interactions between the enzyme and DFMO.
Citation: Jhingran A, Padmanabhan PK, Singh S, Anamika K, Bakre AA, et al. (2008) Characterization of the Entamoeba histolytica Ornithine Decarboxylase-Like
Enzyme. PLoS Negl Trop Dis 2(1): e115. doi:10.1371/journal.pntd.0000115
Editor: Anuradha Lohia, Bose Institute, India
Received: February 13, 2007; Accepted: October 4, 2007; Published: January 2, 2008
Copyright:  2008 Jhingran et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work carried out in this paper was supported by a grant from the Council of Scientific and Industrial Research, Government of India, New Delhi,
India to RM. Senior Research Fellowships from the Council of Scientific and Industrial Research, India supported AM, SS and KA.
Competing Interests: The authors have declared that no competing interests exist.
*E-mail: madhubala@mail.jnu.ac.in
Introduction
Entamoeba histolytica is a unicellular protozoan parasite that
infects about 50 million people each year and may cause
potentially life-threatening diseases such as hemorrhagic colitis
and/or extraintestinal abscesses [1]. The infections are primarily
treated by antiamoebic therapy. Drugs of choice for invasive
amoebiasis are tissue-active agents such as metronidazole,
tinidazole, and chloroquine [2]. Although drug resistance to E.
histolytica does not appear to be a serious problem, there are
occasional reports of failure with metronidazole suggesting the
possibility of development of clinical drug resistance [3].
Polyamine biosynthetic pathway is the critical regulator of cell
growth, differentiation, and cell death [4–6]. Polyamines are
involved in nucleic acid packaging, DNA replication, apoptosis,
transcription, and translation [7]. The polyamine biosynthetic
pathway is a potential target for therapeutic agents against various
hyperproliferative disorders, particularly cancer [8–10]. Given the
importance of the polyamine biosynthetic pathway as a validated
therapeutic target in protozoan parasites [11–14], we decided to
further investigate this pathway in E. histolytica in the hope of
extending our attempts at drug discovery to include this medically
important parasite.
Ornithine decarboxylase (ODC; EC 4.1.1.17) is the first rate-
limiting enzyme in polyamine biosynthesis, catalyzing the
decarboxylation of L-ornithine to putrescine. This enzyme is
found in a variety of systems ranging from bacteria [15] and
protozoa [16] to plants [17] and mammals [18]. The rapid
activation of the enzyme by various stimuli such as hormones,
growth factors, or stress makes this enzyme a vital mediator in the
regulation of polyamine pathway. ODC, like most amino acid
decarboxylases, requires pyridoxal-59-phosphate (PLP) as a
cofactor [19]. E. histolytica ODC protein has been biochemically
purified from trophozoites of the parasite [20]. Analytical
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electrophoresis revealed the presence of a major polypeptide of
45 kDa and scarcely noticeable amounts of two other proteins of
70 and 120 kDa. The major polypeptide exhibited amino-terminal
sequence homology in the range of 40%–73% with ODCs of other
organisms [20].
Biosynthesis of polyamines in parasites has been exploited as a
target to control disease caused by several parasites with specific
inhibitors of ODC such as a-difluoromethylornithine (DFMO),
which is a structural analog of ornithine. DFMO has been found
to be an efficient therapeutic agent against ODC up-regulation
[13,14,21–23]. It is a specific and irreversible inhibitor of ODC,
and previous studies have shown that DFMO inhibits growth of
Giardia lamblia [24], Acanthamoeba castellani [25], Plasmodium
falciparum, and some Trypanosoma species [13,14,21,26] but has
no inhibitory effect on E. histolytica ODC [20].
In this paper we report, to our knowledge for the first time,
molecular cloning, expression, and characterization of a putative
ODC-like sequence from E. histolytica, the parasitic protozoan
responsible for amoebiasis. ODC is a PLP-dependent enzyme, and
in the present work the ability of E. histolytica putative ODC to
form complexes with PLP and DFMO was investigated using
modeling of the three-dimensional structure.
Materials and Methods
Reagents
Restriction enzymes Pfu and Taq DNA polymerases were
obtained from MBI Fermantas. All other chemicals were of
analytical grade and were available commercially.
Parasite and culture conditions
All experiments were carried out with E. histolytica strain HM-
1:IMSS clone 6, which was obtained from William A. Petri
(University of Virginia). The cells were maintained and grown in
TYI-33 medium supplemented with 15% adult bovine serum, 2%
Diamond’s vitamin mix, and antibiotic (0.3 units/ml penicillin and
0.25 mg/ml streptomycin). Cell viability was determined by
microscopy using a trypan blue dye exclusion test. Experiments
were conducted with cells that showed .90% viability.
Cloning of putative ODC-like gene sequence from E.
histolytica
A ,1,242 base pair fragment was amplified from the genomic
DNA of E. histolytica using a sense primer with flanking BamH I
site (underlined), 59-CGCGGATCC ATGAAACAAACATCTC-
TAGAAG-39, which codes for amino acid sequence MKQTSLE
at position 1–21 and one extra base, G, and the antisense primer
with a flanking Xho I site (underlined), 59- CCGCTCGAGAG-
CATAGTGTGGAATACCAT-39, which codes for amino acids
GIPHYA at position 1,220–1,239 with two extra bases, A and T.
Polymerase chain reaction was performed in a 50 ml reaction
volume containing 150 ng of genomic DNA, 25 pmol each of
gene-specific forward and reverse primers, 200 mM of each
dNTPs, 2.5 mM MgCl2, and 2.5 units of Taq DNA Polymerase
(MBI Fermentas). PCR cycling conditions were as follows; 94uC
for 10 min, followed by 35 cycles of 94uC for 1 min, 47uC for
45 sec, 72uC for 1:30 min. A final extension was carried out for
10 min at 72uC. A single 1,242 bp PCR product was obtained and
subcloned into pTZ57R T/A vector (Promega, Madison, USA) and
subjected to automated sequencing. Sequence analysis was per-
formed by DNAstar, whereas comparisons with other sequences of
the database were performed using the search algorithm BLAST
[27]. Multiple alignments of amino acid sequences were performed
using CLUSTAL W (http://www.ebi.ac.uk/clustalw/). The phylo-
genetic tree was constructed using PHYLIP style treefile produced by
CLUSTAL W. The ,1242-bp DNA fragment, amplified by Pfu
polymerase (MBI Fermentas), was also cloned into the BamH I-Xho
I site of pET 30a vector (Novagen). The recombinant construct was
transformed into BL21 (DE3) strain of E. coli.
Expression and purification procedure
Expression from the construct pET30a-ODC-like sequence was
induced at O.D. of 0.3 with 1 mM IPTG (isopropyl b-D-
thiogalactoside) (Sigma) at 37uC for different time periods.
Bacteria were then harvested by centrifugation and the cell pellet
was resuspended in binding buffer (50 mM sodium phosphate
buffer, pH 7.5; 10 mM imidazole, pH 7.0; 300 mM sodium
chloride; 2 mM phenylmethylsulphonyl fluoride (PMSF); and
30 ml protease inhibitor cocktail). Lysozyme (100 mg/ml) was added
to the cell suspension and kept on a rocking platform for 30 min at
4uC. The resulting suspension was sonicated six times for 20 s with
1 min intervals. The lysate was centrifuged at 20,000g for 30 min at
4uC. The resulting supernatant, which contained protein, was
loaded onto a pre-equilibrated Ni-NTA agarose beads (Ni2+-
nitrilotriacetate)-agarose beads (Qiagen). The mixture was kept on
a rocking platform for 2 h at 4uC. It was centrifuged at 400 g for
30 min at 4uC. The supernatant was discarded and pellet was
washed thrice with wash buffer (50 mM sodium phosphate buffer,
pH 7.5; 50 mM imidazole, pH 7.0; 300 mM sodium chloride;
2 mM phenylmethylsulphonyl fluoride [PMSF]; and 30 ml protease
inhibitor cocktail). The protein was eluted with increasing
concentrations of imidazole, pH 7.0. The imidazole was removed
by dialysis in 20 mM sodium phosphate buffer, pH 7.5. The purified
protein was aliquoted and stored at 280uC.
Nucleic acid isolation, pulsed-field gradient gel
electrophoresis, and hybridization analysis
Genomic DNA was digested with the enzymes XhoI and
HindIII and subjected to electrophoresis in 0.8 % agarose gels.
The fragments were transferred to nylon membranes (Amersham
Pharmacia Biotech) and subjected to Southern blot analysis. For
Northern blot analysis, 15 mg of total RNA was fractionated by
denaturing agarose gel electrophoresis and transferred onto nylon
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membrane following standard procedures. Pulsed-field gradient
gel electrophoresis (PFGE) was carried out essentially as described
earlier [28]. The agarose blocks containing the cells were subjected
to PFGE in 1.2% agarose gels using the Gene Navigator system
(Pharmacia). The pulse conditions used were 70 s for 15 h, 120 s
for 14 h, and 200 s for 7 h at 5.5 V cm21. Saccharomyces cerevisiae
chromosomes were used as size markers. Following the transfer of
DNA, RNA, and chromosomes onto nylon membranes, the
nucleic acids were UV cross-linked to the membrane in a
Stratagene UV cross-linker. Prehybridization was done at 65uC
for 4 h in a buffer containing 0.5 M sodium phosphate; 7% SDS;
1mM EDTA, pH 8.0; and 100 mg/ml sheared denatured salmon
sperm DNA. The blots were hybridized with denatured a-
[PPPP32P]-dCTP-labeled DNA probe (PCR probe described for
the E. histolytica putative ODC-coding region) at 10PP6P cpm/ml,
which was labeled by random priming (NEB BlotPPKit, New
England Biolabs). Membranes were washed, air-dried, and
exposed to an imaging plate. The image was developed by
PhosphorImager (Fuji film FLA-5000, Japan) using Image Quant
software (Amersham Biosciences).
Preparation of crude extract of E. histolytica for ODC assay
E. histolytica (16106 cells) were harvested by centrifugation at
16,000 g at 4uC for 10 min, washed with phosphate-buffered
saline, pH 7.4. The cell pellet was resuspended in lysis buffer
(100 mM Tris-Cl, pH 7.5; 150 mM sodium chloride; 2 mM
PMSF; 2 mM iodoacetamide; 2 mM EDTA; 2.5 mM parahy-
droxymercuricbenzoic acid; 2 mM ethylene glycol-bis (amino
ether); and 10 mg/ml proteinase cocktail) and incubated on ice for
10 min. The cells were lysed by freeze-thaw in liquid nitrogen and
subjected to sonication for 10 sec with 1 min interval at 4uC,
thrice. The lysate was centrifuged at 15,000g for 30 min at 4uC
and the supernatant was used for ODC assay, polyamine
estimation, and Western blot analysis as mentioned below.
ODC assay
ODC activity was assayed by following the release of 14CO2
from L- [-14C] ornithine [29]. The standard assay mixture
containing the supernatant, 200 mM PLP; 12.5 mM DTT;
250 mM Tris, pH 7.5; 2 mM ornithine; and 3 mCi of the
radiolabeled ornithine were incubated at 37uC for 1 h. The
reaction was terminated by injecting 5 N H2SO4. Activity is
expressed in enzyme units in which one unit is nmol of CO2 /mg
protein/h. The assay was repeated thrice. Protein concentrations
were determined by the method of Bradford [30] using bovine
serum albumin as standard.
Polyamine analysis
Quantitative determination of polyamines in crude lysates of E.
histolytica was performed by C18 reversed-phase high performance
liquid chromatography after precolumn derivatization with dansyl
chloride [31]. The results were based on three separate
determinations.
Antibody production
The purified recombinant putative ODC-like protein (20 mg)
was subcutaneously injected in mice using Freund’s complete
adjuvant, followed by two booster doses of recombinant putative
ODC-like protein (15 mg) with incomplete adjuvant at 2 wk
intervals to produce polyclonal antibody against the recombinant
putative ODC-like protein. The mice were bled after 2 wk after
the second booster, and sera were collected and used for Western
blot analysis.
Western blot analysis
Recombinant putative ODC-like protein and cell lysate (100 mg of
protein) from E. histolytica were fractionated by SDS/PAGE blotted
on to nitrocellulose membrane using electrophoretic transfer cell
(Bio-Rad). Western blot analysis was carried out using the ECL
(enhanced chemiluminescence) kit (Amersham Biosciences) accord-
ing to the manufacturer’s protocol. Anti-polyhistidine (mouse IgG2a
isotype, Sigma) and polyclonal antibody (1:500 dilution) against
purified recombinant E. histolytica putative ODC generated in mice
were used for Western blot analysis.
Structural modeling of E. histolytica putative ODC and
analysis of the binding site
The structure of the Trypanosoma brucei ODC mutant in complex
with DFMO [32] was used as a template to model E. histolytica
ODC. In this mutant structure, lysine 69 has been mutated by
alanine (K69A). STAMP (structural alignment of multiple
proteins) [33], was used for structural alignment of three ODCs
from T. brucei (2TOD) (ExPASy [http://expasy.org/] accession
number: P07805), H. sapiens (1D7K) (ExPASy accession number:
P11926) and M. musculus (7ODC) (ExPASy accession number:
P00860). Later, the program JOY (version 5) [34] was used to
align and merge three structurally aligned ODCs with the
sequence of E. histolytica putative ODC such that properties of
both the structure-based alignment for the homologues of known
three-dimensional structures and the sequence-based alignment
involving E. histolytica putative ODC are reflected in the final
alignment used for modeling (Figure 1A). JOY represents
structural information and annotates each amino acid residue
according to its structural environment. JOY uses local structural
features calculated from the atomic coordinates in a PDB file. The
three-dimensional model of E. histolytica putative ODC in complex
with PLP and DFMO has been built based on the crystal structure
of T. brucei ODC by using the program MODELLER [35].
MODELLER generates a three-dimensional structure of a given
protein sequence (target) based primarily on its alignment to one
or more proteins of known structure (template/templates). The
modeling process consists of fold assignment, target-template
alignment, structure building, and evaluation. MODELLER
implements comparative protein structure modeling by satisfying
spatial restraints [36,37] and performs tasks such as de novo
modeling of loops, comparison of protein structures, optimization
of various models of protein structures, etc. Interactive graphics
like SYBYL (Tripos, St. Louis, Missouri, United States) was used
for energy minimization of the modeled structure to relieve the
short contacts, if any.
Energy minimization
Modeled E. histolytica putative ODC was subjected to energy
minimization using the AMBER force field [38] encoded in the
SYBYL software. Energy minimization was done in order to
rectify all stereochemical inconsistencies and short contacts that
may be present in the initial model.
Results
Sequence analysis and genomic organization
In order to clone the gene encoding putative ODC-like gene,
PCR was performed using specific oligonucleotides (as described
in the Methods section), whose sequence was based on Genome
Sequencing Project of E. histolytica (http://www.tigr.org). Exam-
ination of the E. histolytica database predicts a single ODC gene
(http://pathema.tigr.org). A single open reading frame consisting
of ,1,242 bp was obtained, cloned, and sequenced. (E. histolytica
Novel Drug Target of Entamoeba histolytica
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ODC gene, GenBank [http://www.ncbi.nlm.nih.gov/Genbank/]
accession number AY929249).
The open reading frame coded for a putative polypeptide of 413
amino acids, with a predicted molecular mass of ,46 kDa. The
predicted isoelectric point (pI) of E. histolytica putative ODC-like
protein (GenBank accession number AAX35675) was determined
to be 5.61, comparable to those of proteins from L. donovani
(GenBank accession number P27116) (pI 5.29), and T. brucei
(GenBank accession number AAA30219) (pI 5.46) (Figure 1).
There was only 33% sequence identity with human ODC
(GenBank accession number AAA59967), 32% identity with T.
brucei (GenBank accession number AAA30219), and 36% identity
with Datura stramonium ODC (GenBank accession number
CAA61121) sequences (Figure 1B). The sequences of the
mammalian ODC has some highly conserved amino acids and
regions that are reported to be essential for catalytic activity and
dimerization [39–41], and these were also found in the putative
ODC-like sequence of E. histolytica. The putative ODC-like
sequence was 413 amino acids smaller than ODCs from T. brucei,
Homo sapiens, and D. stramonium (Figure 1B). The residue that is
essential for dimerization of ODC monomers, mediated by
glycine-387 in mammals [42], was found to have equivalents in
the sequence of the E. histolytica putative ODC-like protein at
position glycine-361. The sequence motif PFYAVKCN at position
64–71 of mammalian ODC, which contains the lysine-69 residue
to which the cofactor pyridoxal-59-phosphate binds, is present at
position 53–60 of the E. histolytica putative ODC-like protein,
although with changes of phenylalanine to cysteine and tyrosine to
phenylalanine. The region GPSCNGSD at position 331–338 in
the E. histolytica putative ODC-like protein is probably equivalent
                               10        20        30        40        50
2toda_1    (  37 )                                       gdpfFvAdlGdIvrK
1d7ka      (   7 ) eefdchfldegftakdiLdqkInevsssddkdAfYVAdLgdILkk
7odca_1    (   2 )    ssftkdefdChILdegftakdILdqk-i---n--dkdAfYVAdLGdILkK
36.t00008             -----------MKQTSLEVKEFALNLISQFEPENQPLGFWIFDTEGVEKA 
                                                            bbbbbaaaaaaa 
                               60        70        80        90        100
2toda_1    (  52 ) hetWkkcLprVtpfYaVaCNddwrVLgtLaalgTGFdCasnteIqrVrgi
1d7ka      (  52 )    HlrWlkaLprVtPFYA-VCNdskAIVkTLaaTgTGFdCaskteIqlVqsl
7odca_1    (  52 )    hlrWlkALprVtPFYaVkCNdsrAIVSTLaaigTGFdCaskteIqlVqgL
36.t00008             VERWKKNMPTVRPCFAVKCNPEPHLVKLLGELGCGFDCASLNEIKEVLDL 
                      aaaaaaa   bbbbbb      aaaaaaaaa   bbbb  aaaaaaaa
                               110       120       130       140       150
2toda_1    ( 102 ) gVppekIiYAnPcKqishIryArdSgVdvMTFdcvdELekVaktHpkAkM
1d7ka      ( 102 ) gVpperIIYAnPcKqvsqIkyAanngVqmMTFdsevELmkVarAHpkAkL
7odca_1    ( 102 ) gVpaerVIYAnPcKqvsqIkyAasngVqmMTFdseiELmkVarAHpkAkL
36.t00008             GFNPEDITYSQTFKPYNQLIEASHLGINHTIVDSIDEVQKIAKYAPKMGI 
                         333bbb      aaaaaaaaa    bbbb  aaaaaaaaaa    bb 
                               160       170       180       190       200
2toda_1    ( 152 )    VLrI-stL---------svkfGakvedCrfiLeqAkklnIdVTGVSFhVg
1d7ka      ( 152 )    VLrIatd-dskavcrls-vkfGatlrtSrlLLerAkelnIdVvGVSFhVg
7odca_1    ( 152 )    VLrI-------------atkfGatlktSrlLLerAkelnIdViGVSFhVg
36.t00008             MIRIMENDTSAGHVFGE--KFGLHDDEVEIVLKEIKDKGLNLDGVHFHVG 
                      bbb                     aaaaaaaaaaaaa   bbbbbb
                               210       220       230       240       250
2toda_1    ( 200 )    sgstdastFaqAIsdSrfVFdmGtelgfnMhiLDIGGGFpGtrdaplkFe
1d7ka      ( 200 )    sgCtdpetFvqAIsdArcVFdmGaevgFsMyLLDIGGGFpGsedvklkFe
7odca_1    ( 200 )    sgctdpdtFvqAVsdArcVFdmAteVgFsMhLLDIGGGFpGsedtklkFe
36.t00008             SDSHNSEVFTKALTKARNTVTLAEQFGMKPYLIDIGGGFS----QVAPFE 
                            aaaaaaaaaaaaaaaaaaa      bbb              aa 
                               260       270       280       290       300
2toda_1    ( 250 ) eIAgvInnaLekhFp-pdlkltIVAePGrYYVasAFtLaVnViakkvt--
1d7ka      ( 250 )    eITgvInpaLdkyFpsd-sgVrIIAEPGrYYVasAFtLAVNIiakkivlk
7odca_1    ( 250 )    eITsvInpALdkyFpsd-sgVrIIAePGrYYVasAFtLAVNIiakktv--
36.t00008             EFAATIEKTIKELEFPER--TRFIAEPGRYMASNAFHLVSSLHGKRVRIQ 
                      aaaaaaaaaaaaa        bbbb   aaaa333bbbbbbbbbbbbb
                               310       320       330       340       350
2toda_1    ( 297 )    ---paqsFmYyVndGvygSFNCilydhavvrPlpqrepipneklypSsVw
1d7ka      ( 299 ) eqte-qtFmYyVndGvygSFNCilydhahvkpllqkrpkpderyysSsIw
7odca_1    ( 297 )    --we-qtFmYyVndGvygSFNCilydhahvkAllqkrpkpdekyysSsIw
36.t00008             NGKK--QIEYTSGDGLHGSFGCCIWFEKQKSCECITQKVNENKMYESIIY 
                            bbbbbb         aaaa       bb          bbbbbb 
                               360       370       380       390       400
2toda_1    ( 357 )    GpTcdglDqIveryyLpeMqvgewLlFedMGAyTvvgtssfngfqsPtiy
1d7ka      ( 357 )    GPTcdglDrIvercdLpeMhvgdWMLFenMGAyTvaaAstfngfqrptiy
7odca_1    ( 357 )    GPTcdglDrIvercnlPeMhvgdwMlFenMGAyTvaaAstfngfqrpniy
36.t00008             GPSCNGSDKVAT-QELPEMEPGKDWLLFPNMGAYTISMATNFNGFEERNI 
                              bbbbbbbb       bbbb       333   333    bbb 
                               410       420
2toda_1    ( 407 )    yvvs
1d7ka      ( 407 )    YVMsgpawqlmqqfqnpdfpp
7odca_1    ( 407 )    yVMsrpmwqlMk
36.t00008             YTLPLKSTKIIQIPKSIECNS 
                      bb
a
Human            1 -------------------------MNNFGNEEFDCHFLDEGFTAKDILDQKINEVSSSD
T.brucei         1 -------------------------MDIVVNDDLSCRFLEG-FNTRDALCKKISMN-TCD
Datura           1 MAGQTVIVSGLNPAAILQSTIGGATPAPAAENDHTRKVVPLSRDALQDFMVSIITQKLQD
E.histolytica    1 -------------------------------------MKQTSLEVKEFALNLISQFEPEN
Human           36 DKDAFYVADLGDILKKHLRWLKALPRVTPFYAVKCNDSKAIVKTLAATGTGFDCASKTEI
T.brucei        34 EGDPFFVADLGDIVRKHETWKKCLPRVTPFYAVKCNDDWRVLGTLAALGTGFDCASNTEI
Datura          61 EKQPFYVLDLGEVVSLMDQWNAGLPNIRPFYAVKCNPEPSFLSMLSAMGSNFDCASRAEI
E.histolytica   24 QPLGFWIFDTEGVEKAVERWKKNMPTVRPCFAVKCNPEPHLVKLLGELGCGFDCASLNEI
- - - - - - - - 
Human           96 QLVQSLGVPPERIIYANPCKQVSQIKYAANNGVQMMTFDSEVELMKVARAHPKAKLVLRI
T.brucei        94 QRVRGIGVPPEKIIYANPCKQISHIRYARDSGVDVMTFDCVDELEKVAKTHPKAKMVLRI
Datura         121 EYVLSLGISPDRIVFANPCKPESDIIFAAKVGVNLTTFDSEDEVYKIRKHHPKCELLLRI
E.histolytica   84 KEVLDLGFNPEDITYSQTFKPYNQLIEASHLGINHTIVDSIDEVQKIAKYAPKMGIMIRI
Human          156 A-TDDSKAVCRLSVKFGATLRTSRLLLERAKELNIDVVGVSFHVGSGCTDPETFVQAISD
T.brucei       154 S-TDDSLARCRLSVKFGAKVEDCRFILEQAKKLNIDVTGVSFHVGSGSTDASTFAQAISD
Datura         181 KPMDDGNARCPMGPKYGALPEEVEPLLRTAQAARLTVSGVSFHIGSGDADSKAYLGAIAA
E.histolytica  144 M-ENDTSAGHVFGEKFGLHDDEVEIVLKEIKDKGLNLDGVHFHVGSDSHNSEVFTKALTK
Human          215 ARCVFDMGAEVGFS-MYLLDIGGGFPGSEDVKLKFEEITGVINPALDKYFPSDSGVRIIA
T.brucei       213 SRFVFDMGTELGFN-MHILDIGGGFPGTRDAPLKFEEIAGVINNALEKHFPPDLKLTIVA
Datura         241 AKGVFETAARFGMSKMTVLDIGGGFTSG----HQFTTASAAVRSALEQHFHDEQELTIIA
E.histolytica  203 ARNTVTLAEQFGMK-PYLIDIGGGFSQVAP----FEEFAATIEKTIKELEFPER-TRFIA
Human          274 EPGRYYVASAFTLAVNIIAKKIVLKEQTGSDDEDESSEQTFMYYVNDGVYGSFNCILYDH
T.brucei       272 EPGRYYVASAFTLAVNVIAKKVTPGVQTDVGAHAESNAQSFMYYVNDGVYGSFNCILYDH
Datura         297 EPGRFFAETAFTLATTIIGKRVRG--------------ELREYWINDGLYGSMNCVLYDH
E.histolytica  257 EPGRYMASNAFHLVSSLHGKRVRIQ----------NGKKQIEYTSGDGLHGSFGCCIWFE
Human          334 AHVKPLLQKRPKPDE-------KYYSSSIWGPTCDGLDRIVERCDLPEMHVGDWMLFENM
T.brucei       332 AVVRPLPQREPIPNE-------KLYPSSVWGPTCDGLDQIVERYYLPEMQVGEWLLFEDM
Datura         343 ATVNATPLACMSNRSNLNCGGSKTFPSTVFGPTCDALDTVLRDYQLPELQVNDWLIFPNM
E.histolytica  307 KQKSCECITQKVNEN------TKMYESIIYGPSCNGSDKVATQELPEMEPGKDWLLFPNM
                                                 ***** 
Human          387 GAYTVAAASTFNGFQRPTIYYVMSGPAWQLMQQFQNPDFPPEVEEQDASTLPVSCAWESG
T.brucei       385 GAYTVVGTSSFNGFQSPTIYYVVSGLPDHVVRELKSQKS---------------------
Datura         403 GAYTKAAGSNFNGFNTSAIVTHLAYAYPS-------------------------------
E.histolytica  361 GAYTISMATNFNGFEERNHVIYTLPLKSTKIIQIPKSIECNSVPSLNGIPHYA-------
Human          447 MKRHRAACASASINV 
T.brucei           --------------- 
Datura             --------------- 
E.histolytica      --------------- 
b
Figure 1. Structure-based alignment of ODCs from T. brucei (2toda) (ExPASy accession number: P07805), H. sapiens (1d7ka) (ExPASy
accession number: P11926), M. musculus (7odca) (ExPASy accession number: P00860), and E. histolytica (36.t00008) (GenBank
accession number: Q58P26). (A) The structural environments of the residues in the known structures are encoded in the representation: Upper
case letters are solvent-inaccessible amino acids; lower case letters are solvent accessible; italicized letters are residues with a positive w (one of the
Ramachandran angles); bold letters indicate a side chain hydrogen bonded to the main chain amide; underlined letters indicate a side chain
hydrogen bonded to the main chain carbonyl. The numbers within parenthesis represent the first residue of the given protein in a block. Conserved
a-helical, 310 helical, and b-strand regions are indicated at the end of every alignment block as a, 3, and b respectively. Figure produced using JOY
[34]. (B) Multiple sequence alignment of putative ODC-like sequence from E. histolytica (GenBank accession number AAX35675), T. brucei ODC
(GenBank accession number AAA30219), human ODC (GenBank accession number AAA59967), and Datura stramonium ODC (GenBank accession
number CAA61121) using ClustalW. The amino acids are numbered to the left of the respective sequences. Residues that are identical or similar to
other ODCs are indicated in black showing complete identity, and grey when they are conserved in at least three sequences. Short dashed line below
the sequence represents the pyridoxal phosphate binding site. Line of asterisks (*) represents the DFMO binding site.
doi:10.1371/journal.pntd.0000115.g001
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to consensus sequence GPTCDGLD of the ODC sequences of
various eukaryotes. This sequence contains cysteine-360 in mam-
malian ODC, which is the major binding site of a-difluoromethy-
lornithine (DFMO) [40]. The corresponding cysteine-334 is
conserved in E. histolytica putative ODC-like protein. The overall
amino acid homology of E. histolytica putative ODC with the
mammalian ODC is low, but highly conserved signature motifs
responsible for dimerization and catalytic activity were present.
Another signature sequence, as predicted by PROSITE, D(I/
V)GGGF, is present across varied sequences without exception.
Other highly conserved amino acid stretches, i.e., FDCAS, EPGR,
FNGF, and GAYT, are also consistently conserved, though the
functional significance of these stretches is not known.
A phylogenetic tree was constructed using the E. histolytica
putative ODC-like sequence and other representative ODC
sequences (Figure 2). The nearest homologue to the amoebic
protein, as revealed by the tree, is the plant D. stramonium. The
human ODC sequence seems to be farthest from the amoebic one.
Among kinetoplastids, L. donovani appears to be the closest
homologue, while Trypanosoma not clustering with L. donovani, is
quite distantly related.
To determine the E. histolytica putative ODC-like gene copy
number, Southern blot studies were performed as described in
Materials and Methods, using the 1,242-bp PCR product as a
probe (Figure 3). The enzymes used for Southern analysis were
Xho I and Hind III, which have no recognition sites in the E.
histolytica putative ODC-like gene sequence. A single band was
obtained in each case (Figure 3A), demonstrating that it is a single-
copy gene. A PFGE blot probed with the 32P labeled 1,242 bp
ODC PCR fragment, hybridized to a 1.9 Mb size chromosome.
(Figure 3B). Northern blotting of E. histolytica total RNA and PCR-
generated,1,242-bp gene probe, revealed two transcripts of,4.8
and ,3.5 kb (Figure 3C).
Overexpression and purification of full-length
E. histolytica putative ODC-like protein in E. coli
In order to characterize the recombinant protein, the gene
sequence encoding the E. histolytica putative ODC-like protein was
cloned in-frame in a pET-30a expression vector with its own start
ATG codon. The resultant pET-30a E. histolytica putative ODC-
like construct was transformed into E. coli, and protein expression
was induced as described in Materials and Methods. A protein
with molecular weight that matched the estimated ,48 kDa
Figure 2. Phylogenetic tree using the amino acid sequences of
putative ODC from E. histolytica and ODCs from other
organisms. The TreeView program in the ClustalW displayed the
phyletic trees derived from the multiple alignments.
doi:10.1371/journal.pntd.0000115.g002
Figure 3. Southern blot analysis of E. histolytica putative ODC-like gene. (A) Lanes 1 and 2, restriction digest of E. histolytica genomic DNA
with XhoI and HindIII, respectively. Lane 3 represents the DNA molecular weight marker and sizes are indicated on the right of the figure. The blot
was probed with 1,242 bp full-length putative ODC-like gene. (B) PFGE analysis of E. histolytica indicating chromosomal localization of the ODC gene.
The blot was probed with the putative ODC-like gene probe. The arrow shows a 1.9 Mb hybridizing band of putative ODC. (C) Northern blot analysis
of mRNA from E. histolytica. Lane 1, total RNA from E. histolytica probed with 1,242 bp full-length putative ODC-like gene; lane 2, molecular weight
marker.
doi:10.1371/journal.pntd.0000115.g003
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predicted by the amino acid composition of E. histolytica putative
ODC-like protein with His-tag and S-tag present at its N-terminal
end was induced (Figure 4). The recombinant protein was purified
on a Ni2+-NTA affinity chromatography column (Figure 4A and
4B). To further confirm the size of the protein, a Western blot was
done with anti-His antibody that revealed the band of purified
product (, 48 kDa) (Figure 4C). Recombinant E. histolytica
putative ODC-like protein was used to raise polyclonal antibody
in BALB/c mice as described in Materials and Methods. The
antiserum recognized a ,48 kDa fusion protein on a Western blot
of purified recombinant E. histolytica putative ODC-like fusion
protein (Figure 4D). The same antiserum detected a band of
anticipated E. histolytica putative ODC at size ,46 kDa in Western
blots of parasite cell extracts, in agreement with the value
calculated from the predicted sequence (Figure 4E). Purification
of His-tagged E. histolytica putative ODC-like protein by metal
affinity chromatography yielded ,3–4 mg of pure protein from a
1-liter bacterial culture.
E. histolytica ODC activity
ODC activity was measured in the crude E. histolytica lysates and
in the recombinant putative ODC-like protein. Detailed study was
limited by its remarkable instability. Addition of dithiothreitol
(2 mM DTT), a known stabilizer of mammalian ODC [43], to the
purified enzyme samples did not improve the stability of the
enzyme or its activity. However, we were able to measure the
activity by adding 0.002% BRIJ-35 to the reaction mix. The
activity obtained in the crude lysate was 4.860.8 nmol h21 mg21
protein, and the recombinant protein gave an activity of
1,31167.0 nmol h21 mg21 protein (Table 1). Addition of DFMO
(10 mM) to the recombinant ODC protein did not have any affect
on the ODC activity (1,085615 nmol h21 mg21 protein). The
values obtained were not significantly different from that of the
control with no DFMO. The Km value for the substrate ornithine
was 1.5 mM. The activity obtained here for the recombinant
protein was much lower than that reported earlier for the purified
protein from E. histolytica [20]. Ammonium sulfate purification of
the His-tagged recombinant ODC protein from E. histolytica did
not improve the activity of this recombinant protein. Since we
were not able to obtain higher Km values using ornithine as the
substrate, we checked substrate preference. Decarboxylation of L-
arginine and L-lysine was also measured in order to check the
substrate preference of the recombinant protein. In the ODC
assay we found no activity using arginine and lysine as the
substrate.
Figure 4. Overexpression and purification of E. histolytica putative ornithine decarboxylase-like protein. (A) Coomassie blue staining of
SDS/PAGE showing overexpression of full-length E. histolytica putative ODC-like protein in E. coli. The pET 30a bacterial extract after induction (lanes 1
and 2) at 3 h and 1 h, respectively with 1mM IPTG and before induction (lane 3). The arrow shows the induced recombinant putative ODC-like
protein. The broad-range protein MW marker (lane 4) (BioRad) was used to identify the size of recombinant protein. (B) Purification of putative ODC-
likeprotein on Ni2+ affinity resin. Lanes 1–4, eluted fractions showing purified putative ODC-like protein from affinity column; lanes 5, 6, and 8 are
washes; lane 7, broad-range protein MW marker (BioRad); lane 9, supernatant from the crude lysate. (C) Western blot using anti-His antibody. Western
blot analysis of different concentrations of purified putative ODC-His fusion recombinant protein. Lanes 1–5 represent 25, 20, 18, 15, and 5 mg of
recombinant proteins, respectively. (D) Western blot using anti-E. histolytica ODC. Lanes 1–3 represent 2, 3, and 6 mg of purified recombinant protein.
Prestained broad-range protein molecular weight marker (BioRad) was used to identify the size of the protein on the Western blot. (E) Western blot
using anti-E. histolytica ODC. Lane 1, purified recombinant protein. Lane 2, E. histolytica lysate. Prestained broad range protein molecular weight
marker (BioRad) was used to identify the size of the protein on the Western blot.
doi:10.1371/journal.pntd.0000115.g004
Table 1. Analysis of ODC activity and polyamine levels of
E. histolytica
Sample
ODC activity (nmol h21
mg21 protein)
Intracellular polyamine levels
(nmol mg21 protein)
Putrescine Spermidine
Crude lysate 4.860.8 13766.4 6.960.2
Levels of polyamines in the lysates were detected by high-performance liquid
chromatography (HPLC). Results are mean6standard deviation values of three
independent determinations.
doi:10.1371/journal.pntd.0000115.t001
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Polyamine levels in E. histolytica
Analysis of polyamine content of E. histolytica revealed substantial
levels of putrescine (13766.4 nmol/mg protein) compared to
spermidine, which is present in very low amounts (6.960.2 nmol/
mg protein). Spermine was not detected in the lysate (Table 1).
Structural analysis of E. histolytica putative ODC
E. histolytica putative ODC-like protein is 413 amino acids long,
with 32% sequence identity with the ODCs of T. brucei and H. sapiens.
We looked for two important motifs in the sequence of ODC that are
essential for binding of DFMO and PLP. The homologues of known
three-dimensional structure complexed with DFMO show that the
amino acid motif GPSCNGSD corresponds to the binding site for
DFMO. DFMO is known to bind to cysteine in this motif. This
cysteine is well conserved in the ODC from all three organisms (T.
brucei, H. sapiens, and E. histolytica). Despite the presence of the
cysteine, E. histolytica putative ODC is not inhibited by DFMO.
Concentration of DFMO as high as 10 mM did not inhibit the
enzyme activity in vitro. The lysine in the PCFAVKCN motif is an
important residue for the interaction of PLP with ODC, which is well
conserved in ODC from all three organisms discussed above.
Structural analysis of the E. histolytica putative ODC is shown in
Figure 5. Known three-dimensional structural analysis suggests that
DFMO, which can inhibit T. brucei ODC, makes a hydrogen bond
(H-bond) with three residues in the two chains of ODC. The
nitrogen (e) of DFMO forms an H-bond with aspartate-332, and
water mediates H-bonds with aspartate-361 and tyrosine-323, both
from the same chain (Figure 5A). All the three residues mentioned
above with which DFMO is interacting are replaced in E. histolytica
putative ODC. Tyrosine-323, aspartate-332, and aspartate-361 of
the T. brucei ODC are substituted by histidine-296, phenylalanine-
305, and asparagine-334 respectively in the E. histolytica putative
ODC. The distance between the nitrogen atom (e) of DFMO and
asparagine-334 is more than 3.4A˚ in E. histolytica and hence unable to
form an H-bond. These three residues have been labeled in the
modeled structure (Figure 5B) of E. histolytica.
It should be noted that a deliberately unrealistic model of the E.
histolytica putative ODC in complex with DFMO was generated in
order to understand why DFMO does not bind to E. histolytica
putative ODC. The overall conformation of modeled E. histolytica
putative ODC in complex with DFMO and PLP is not very
different from that of the T. brucei ODC. The site of PLP binding is
fully conserved, thus E. histolytica putative ODC should be able to
accommodate it. It is possible that the substitution of important
interacting amino acids in E. histolytica putative ODC, makes
DFMO unable to bind and hence unable to inhibit the action of E.
histolytica putative ODC. However, this mechanism can be
experimentally proved only by mutating these residues, namely
histidine-296, phenylalanine-305, and ssparagine-334, respective-
ly, and determining if the inhibition is restored.
Discussion
The polyamines putrescine, spermidine, and spermine are
polycationic organic compounds present in all eukaryotic cells,
including parasitic protozoans. It was reported earlier that the
polyamines are essential for the proliferation of normal cells and
for differentiation [6].
Ornithine decarboxylase is the rate-limiting enzyme in the de
novo synthesis of polyamines and it catalyses the decarboxylation
of ornithine to putrescine and is a highly regulated enzyme.
Interest in ODC has arisen mainly from the observation that the
development of certain tumors closely correlates with increase in
enzyme activity and that specific inhibitors of ODC reduce or stop
these malignancies [13]. In addition, because of the critical role of
ODC in growth and differentiation of the cells, it has been exploited
as a target to control certain parasitic infections with specific
inhibitors of ODC such as DFMO, a structural analog of ornithine
that has been proved as an efficient therapeutic drug [21].
In this paper, we describe the molecular cloning and
characterization of putative ODC-like gene of E. histolytica, a
protozoan parasite known for causing amoebiasis. We cloned the
putative ODC-like gene of E. histolytica (GenBank accession number
AY929249), and there is only 33% identity to H. sapiens ODC.
Comparison of the putative ODC-like protein sequence from E.
histolytica with other eukaryotic species revealed conserved regions.
The sequence PFYAVKCN, which resembles the consensus
sequences of PXXAVKC(N), contains the lysine (K) to which
the pyridoxal 59 phosphate cofactor binds. Other highly conserved
amino acid stretches, for example, FDCAS, EPGR, and FNGF,
are also conserved, although their functional significance of these
stretches is not known. Phylogenetic tree analysis showed a close
evolutionary relationship of ODC of E. histolytica and the plant D.
stramonium. However, comparison of E. histolytica putative ODC-
like sequences with L. donovani and H. sapiens showed closer
evolutionary relationship with L. donovani.
The recombinant putative ODC from E. histolytica was very
unstable. Addition of 2 mM DTT to the enzyme samples did not
improve the activity or stability of this enzyme. Earlier reports also
show that purified ODC from trophozoites of E. histolytica lost most
of the activity after 24 h in unfractionated samples and was
reported to be very unstable [20]. In our hands even ammonium
sulfate purification of the His-tagged recombinant putative ODC-
like protein from E. histolytica did not improve the activity of this
recombinant protein. The irreversible inhibitor DFMO (a-
difluoromethylornithine) did not inhibit activity of E. histolytica
recombinant ODC (data not shown). Similar observations made
previously rules out the possibility of its being used as a suitable
target for this enzyme [20].
It has been reported that purified preparations of E. histolytica
ODC contain a major polypeptide band of 45 kDa and barely
detectable amounts of two other proteins of 70 and 120 kDa. Both
the 45 and the 70 kDa bands were recognized by a mouse anti-
ODC monoclonal antibody [20]. However, in the present study,
Western blot analysis of the whole cell lysates of E. histolytica using the
polyclonal antibody against E. histolytica putative ODC-like enzyme
showed a single band of approximately 46 kDa, and the same
antibody recognized the recombinant protein of about 48 kDa, the
expected size of the putative ODC-His tag fusion protein.
Analysis of polyamine content of E. histolytica revealed significant
levels of putrescine compared to spermidine, which is present in
very low amounts. Spermine was not detected in the lysates.
Computer modeling revealed that three of the critical residues
required for binding of DFMO to the ODC enzyme are
substituted in E. histolytica resulting in the likely loss of interactions
between the enzyme and DFMO. These residues correspond to
Tyrosine-323, Aspartate-332 and Aspartate-361 in T. brucei ODC
homologue and these are substituted by histidine-296, phenylal-
anine-305, and asparagine-334 respectively in E. histolytica
homologue. It is known that Asp-332 and Asp-361 are essential
catalytic residues that interact with the substrate [44]. Several
members of the ODC family are known to be found in the
GenBank database with amino acid substitutions at the position of
Asp-332 (D332E) [45]; however, our present study shows that
amino acid substitution at Asp-361 (an active site) is unique to E.
histolytica putative ODC. Asp-332 is highly conserved in the ODC
family and is known to play an important role in substrate binding
and catalysis. Shah et al. [45] reported that in Paramecium bursaria
Novel Drug Target of Entamoeba histolytica
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Figure 5. Structural analysis of E. histolytica putative ODC. (A) Close up view of DFMO (red) and PLP (magenta) binding sites in the crystal
structure of T. brucei ODC. The two chains of T. brucei ODC are shown in blue and orange. Positions of two water molecules are labeled W1 and W2.
Hydrogen bonding is shown in dashed lines. Distances are represented in angstroms (N-e-of DFMO with W1 : 2.70 A˚; W1 with Tyr : 2.75 A˚; N-e-of
DFMO with Asp-332 : 2.89 A˚; N-e-of DFMO with W2 : 3.15 A˚; W2 with OD2 of Asp 361: 2.99 A˚; W2 with OD1 of Asp-361: 2.89 A˚) (B) Close-up view of
DFMO and PLP binding sites in the modeled structure of E. histolytica putative ODC. The color coding is same as mentioned in Figure 5A. The
modeled structure was generated using the program MODELLER. The distance between N-e of DFMO and Asn-334 is more than 3.5A˚. Note that the
structure with DFMO bound is a deliberate generation of a model corresponding to an unrealistic situation. This figure has been generated using
PyMOL [47].
doi:10.1371/journal.pntd.0000115.g005
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chlorella virus-1 ornithine decarboxylase (PBCV-1 DC) the
equivalent position is residue 296, which is glutamate; according
to the authors this substitution was a key determinant in the
change in the substrate specificity from ornithine to arginine. This
substitution (D332E) has also been observed in sequences of
antizyme inhibitor, which is an inactive ODC homolog that
regulates ODC activity (GenBank accession numbers: human,
NP_680479; mouse, NP_06125; and rat, NP_072107) [46].
Furthermore, they investigated the impact of the active-site
difference at position 332 on substrate specificity and mutated
Asp332 (E296D). They reported that this substitution alone was
insufficient to produce the observed substrate specificity change in
PBCV-1 DC. In the present study we found a unique E. histolytica
substitution in the putative ODC-like gene sequence both at Asp-
332 and Asp-361; given that the amino acid changes affected the
pocket of the E. histolytica enzyme, we wanted to know whether it
was likely to cause a significant change in substrate specificity. We
checked the activity of the recombinant protein using arginine and
lysine as the substrate and found no enzyme activity. Kinetic
analysis using ornithine as the substrate showed lower kinetic
parameters compared to those reported for well-characterized
enzymes from other organisms. It is possible that this enzyme has
evolved a novel substrate specificity. In view of this situation we
feel that this E. histolytica protein might have other functions, so far
unidentified, including a regulatory role.
In conclusion, characterization of the E. histolytica putative
ODC-like enzyme and expression of the protein will facilitate
studies of structural and functional aspects of the enzyme and
could prove to be an important anti-amoebic target.
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